Navigation Links
Neogen Reports 16% Increase in Revenues
Date:7/21/2009

2008 Assets Current assets Cash & securities $13,842 $14,270 Accounts receivable 23,363 19,384 Inventory 31,363 27,799 Other current assets 3,198 4,178 ----- ----- Total current assets 71,766 65,631 Property & equipment 17,058 16,889 Goodwill & other assets 53,352 43,837 ------ ------ Total assets $142,176 $126,357 Liabilities & Stockholders' Equity Current liabilities $9,246 $11,136 Long-term lines of credit - - Other long-term liabilities 4,251 3,973 Stockholders' equity-shares outstanding 14,737 in 2009 & 14,518 in 2008 128,679 111,248 ------- ------- Total liabilities & stockholders' equity $142,176 $126,357

Certain portions of this news release that do not relate to historical financial information constitute forward-looking statements. These forward-looking statements are subject to certain risks and uncertainties. Actual future results and trends may differ materially from historical results or those expected depending on a variety of factors listed in Management's Discussion and Analysis of Financial Condition and Results of Operations in the Company's most recently filed Form 10-K.


'/>"/>
SOURCE Neogen Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related biology technology :

1. Neogen Acquires Kane Enterprises
2. Neogen Reports 25% Increase in Net Income, 13% Increase in Revenues
3. Neogen Acquires Assets of Rivard Instruments
4. Neogen Reports 34% Increase in Net Income, 23% Increase in Revenues
5. Neogen Launches Quickest Test Available for Tetracyclines in Milk
6. NeoGenomics Announces Results for the Fourth Quarter and Full Year FY 2007
7. Webcast Alert: Neogen Corporation Announces 3rd Quarter Results
8. Neogen Reports 34% Increase in Net Income, 20% Increase in Revenues
9. NeoGenomics Files Annual Report on Form 10-KSB with the SEC
10. NeoGenomics Schedules Its Q1 2008 Earnings Release for May 7, 2008
11. Neogen Forms Mexican Subsidiary
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)...  Pharmacyclics, Inc. (NASDAQ: PCYC ) ... newly developed Bruton,s tyrosine kinase (BTK) inhibitor for ... results of these preclinical evaluations have been communicated ... feedback received from the Agency is supportive of ... preclinical work is required to begin a Phase ...
(Date:2/27/2015)... Australia , Feb. 27, 2015 Bionomics ... from the DisrupTOR-1 trial of BNC105 in patients with ... in Orlando, Florida . The data ... of the City of Hope Comprehensive Cancer Center in ... The new data identifies Ferritin and ...
(Date:2/27/2015)... 2015   PureTech , a science and technology ... products and technologies in the healthcare sector, announced today ... and Member of the Board of Directors of Sanofi, ... has been a pleasure to know Chris for many ... be working together more closely now," said Dr. ...
(Date:2/26/2015)... Synageva BioPharma Corp. (NASDAQ: GEVA ... rare disorders, today reported 2014 full year financial ... and financial guidance.  Synageva,s management team will host ... to review the financial results and provide a ... by telephone, please dial (877) 445-4603 for U.S. ...
Breaking Biology Technology:Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 2Pharmacyclics Provides Clinical Update on BTK Inhibitor for Autoimmune Diseases 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 2New BNC105 Biomarker Data to be Presented at US Cancer Conference 3New BNC105 Biomarker Data to be Presented at US Cancer Conference 4New BNC105 Biomarker Data to be Presented at US Cancer Conference 5Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Kosan Biosciences,Incorporated (Nasdaq: KOSN ) announced today ... present at the Leerink Swann,Solid Tumors Roundtable Conference ... on,Friday, May 9, 2008 at 11:10 a.m. EDT. ... through http://www.wsw.com/webcast/leerink15/kosn/ ., Interested parties may ...
... N.C., May 6 There are a lot of ... An organization,s,sales force must be involved with many of ... any successful re-launch effort,according to a study by benchmarking ... a sales force? Half of the companies that,participated in ...
... May 6 , WHAT: ABC,s Dancing with the Stars champion Drew Lachey ... a world leader in diabetes care, to ... diabetes awareness, Dancin, to Change Diabetes. The contest ... that help them stay active and healthy., ...
Cached Biology Technology:Kosan Biosciences to Present at the Leerink Swann Solid Tumors Roundtable Conference 2Invigorated Sales Force Key to a Successful Re-Launch 2Dancing With the Stars' Drew Lachey and Novo Nordisk Launch Dancin' to Change Diabetes National Video Contest 2
(Date:2/5/2015)... , Feb. 3, 2015 Despite ... demand from industries such as consumer electronics, automotive, ... for surface mount technology (SMT) screen printers. Innovations ... automatic control will push the adoption curve up. ... remain steady as glue dispensers are indispensable in ...
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to inform ... State of Washington,s Department of Licensing, in the ... issuance system for driver,s licenses and identification cards to its ... development will start in January 2015, with enrollment and card ...
(Date:1/22/2015)... 13, 2015  Today, FreeWavz ( www.FreeWavz.com ), the ... campaign on Fundable, https://www.fundable.com/freewavz . FreeWavz will ... capacity to meet customer demand. Logo ... http://photos.prnewswire.com/prnh/20150113/168790 Invented by Dr. ...
Breaking Biology News(10 mins):End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 2End-user Demand Spurs Global SMT Screen Printers and Glue Dispensers Market 3Valid USA Signs Contract For Washington Driver's License Issuance 2FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2
... attention. But a study led by McGill researcher Sarah Kimmins ... equally important role in the health of their offspring. It ... diets and of food insecurity. The research focused on ... range of green leafy vegetables, cereals, fruit and meats. It ...
... SAN FRANCISCO, Calif. , Dec. 10, 2013 ... today announced preliminary results of an ongoing multi-center ... (mAb), which the company is developing as a ... disease or who were unfit for chemotherapy have ...
... Whitesides, Ph.D., and David Edwards, Ph.D., have been named ... joining 141 other innovators elected this year. ... to academic inventors who have demonstrated a prolific spirit ... tangible impact on quality of life, economic development, and ...
Cached Biology News:You are what your father eats 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 2KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 3KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 4KaloBios Announces Preliminary Phase 1 Results in Advanced Hematologic Malignancies with KB004, an Anti-EphA3 Monoclonal Antibody 5Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors 2Wyss Institute at Harvard University announces election of 2 faculty to Natl Academy of Inventors 3
Immunogen: Tissue / cell preparation. (Murine EHS laminin preparation) Storage: -20 C, Avoid Freeze/Thaw Cycles...
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
Mouse monoclonal [4i97] to HLA Class 1 A25 ( Abpromise for all tested applications). Antigen: Full length protein (Human): HLA Class 1 Antigen-A25. Swiss Protein ID: P18462...
... choice of Printing Surface (3 glass slides coated with ... 1 silicon wafer coated with 1000 Angstroms of Gold ... and PDMS Stamps (3 PDMS micropatterned stamps with series ... x 10 mm or 200 um x 10 mm ...
Biology Products: